Key Updates in Thrombosis
Table of Contents
In this study—based on the Michigan Anticoagulation Quality Improvement Initiative (MAQI2)—authors sought to determine the effect of stopping aspirin among patients receiving warfarin who were cotreated with aspirin without a strong indication. Advising primary care clinicians to stop aspirin was associated with a reduction in bleeding events compared with pre-intervention periods, without an apparent increase in thrombotic events. Future randomized trials can demonstrate the definitive impact of this interesting observation. Learn more.
Results of the Phase II PACIFIC stroke trial did not show a reduction in the primary composite outcome of covert brain infarction or ischemic stroke in patients assigned to asundexian (a factor XI inhibitor) compared with placebo. Exploratory analyses suggested a potential reduction in recurrent transient ischemic attacks or strokes. Learn more.
Brain tumors such as gliomas are associated with an increased risk of venous thromboembolism (VTE). The authors of a recent systematic review show an association between isocitrate dehydrogenase mutation and a reduced risk of VTE. The postulated mechanisms include a reduction in tissue factor, as well as platelet inhibition. It remains to be seen if targeting this gene by genomic or proteomic approaches can impact the risk of VTE in broader patient populations. Learn more.
Behnood Bikdeli, MD, MS
Cardiologist, Section of Vascular Medicine, Division of Cardiovascular Medicine, Brigham and Women’s Hospital
Investigator, Thrombosis Research Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital
Instructor, Harvard Medical School
Investigator, Yale/ YNHH Center for Outcomes Research and Evaluation, Yale School of Medicine
Investigator, Cardiovascular Research Foundation
Want to find out more about what’s hot in clots this month?
Join us at our in-depth, two-day course Thrombosis and Thromboembolism on October 27 and 28 where world-renowned experts and leading clinical faculty will provide key updates on the prevention, diagnosis, and treatment of thrombosis and related conditions.
This course, offered only once every few years, is intended for all general internists and cardiovascular, peripheral vascular, critical care, pulmonary, surgical, and hematologic specialists who care for patients with thromboses in the venous and arterial systems. The course will be interactive, with time set aside for active discussion with faculty.